drugset / Trial / NCT01449513

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

NCT01449513

Phase 1 Completed 24 enrolled LEO Pharma
RandomizedParallel-groupOpen-labelOther

Summary

This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by reflectance confocal microscopy.

Timeline

Start
2011-09
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator ingenol mebutate Small molecule 0.05 %

Indications